Session

Back to Programme Overview

Checkpoint inhibitors: Summary of latest data in GU cancers

Industry session by BRISTOL-MYERS SQUIBB

  • Location:
    Room London, North Hall (Level 1)
  • Chair:
     M-O. Grimm, Jena (DE)
  • Aims and objectives of this session

    This symposium aims to provide an overview of latest data presented for checkpoint inhibitors in genitourinary cancers (RCC, urothelial cancer). Faculty will also discuss unmet needs and outline ongoing research.

Welcome and introduction
 M-O. Grimm, Jena (DE)
Latest data and ongoing research on checkpoint inhibitors in advanced RCC
 A. Bex, Amsterdam (NL)
Latest data and ongoing research on checkpoint inhibitors in urothelial carcinoma
 J. Bellmunt, Boston (US)
Important information to know for practical use of checkpoint inhibitors
 J. Wagstaff, Swansea (GB)
Discussion and Q&A
 
Panel:
 J. Bellmunt, Boston (US)
 
 
 A. Bex, Amsterdam (NL)
 
 
 M-O. Grimm, Jena (DE)
 
 
 J. Wagstaff, Swansea (GB)
Summary and close
 M-O. Grimm, Jena (DE)